Aptose Bioscienc Stock Price, News & Analysis

Aptose Biosciences (NASDAQ: APTO) announced a webinar on its investigational therapies HM43239 and luxeptinib for treating acute myeloid leukemia (AML) on June 2, 2022. The event will feature leading hematology experts, including Dr. Brian Druker, discussing the treatment landscape and unmet needs in AML. Additionally, Aptose's leadership will provide updates on its two clinical-stage therapies aimed at addressing hematologic malignancies. The company focuses on personalized oncology therapies, with its pipeline including key candidates in clinical trials.

Aptose Biosciences Inc. (NASDAQ: APTO) announced a corporate update for investors on June 2nd at 4:30 PM ET. The session will cover clinical data from two investigational products: HM43239, targeting acute myeloid leukemia (AML), and luxeptinib, for relapsed B-cell malignancies and AML. Additionally, HM43239's preclinical data will be presented on June 10th at the EHA2022 Hybrid Congress in Vienna. Aptose focuses on developing personalized oncology therapies to address unmet medical needs in hematology.

Aptose Biosciences Inc. (NASDAQ: APTO) reported a net loss of $11.5 million for Q1 2022, down from $16.2 million in Q1 2021. As of March 31, 2022, cash and cash equivalents totaled $69.5 million, sufficient to fund operations into Q4 2023. The FDA granted Fast Track designation for its drug HM43239, aimed at treating relapsed acute myeloid leukemia (AML). The company is expanding its cohort for HM43239 and advancing luxeptinib in clinical trials. Additionally, Aptose appointed Dr. Philippe Ledru as Chief Commercial Officer to spearhead future product launches.

Aptose Biosciences announced the FDA granted Fast Track designation to HM43239, an oral kinase inhibitor for relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. This designation aims to expedite HM43239's development, facilitating communication between the FDA and Aptose. Currently, HM43239 is in an ongoing Phase 1/2 clinical trial, showing promise in delivering complete remissions in R/R AML patients, including those resistant to prior FLT3 inhibitors. Aptose remains focused on developing targeted therapies for hematologic malignancies, enhancing treatment options for patients.

Aptose Biosciences announced that Dr. William G. Rice will participate in the 2022 RBC Capital Markets Global Healthcare Conference on May 17, 2022, from 3:30 to 4:00 p.m. ET. The event features a fireside chat moderated by Gregory J. Renza, M.D. The management team will also host 1x1 meetings during the conference. Aptose is a clinical-stage biotechnology company focused on developing targeted therapies for hematologic malignancies. Their pipeline includes two investigational products for treating acute myeloid leukemia and B-cell malignancies.

Aptose Biosciences has announced the publication of three peer-reviewed articles detailing the properties of its investigational drug luxeptinib (CG-806), an oral kinase inhibitor in Phase 1 trials for hematologic malignancies. The publications highlight luxeptinib's ability to inhibit inflammatory pathways and its efficacy against various kinases implicated in B-cell malignancies and acute myeloid leukemia (AML). These findings suggest luxeptinib's potential as a treatment option, especially in resistant cases, reinforcing its clinical development trajectory.

Aptose Biosciences (Nasdaq: APTO; TSX: APS) will report its financial results for the quarter ended March 31, 2022, on May 9, 2022, after market close. The company, focused on precision oncology, is developing oral kinase inhibitors for hematologic malignancies, including HM43239 and luxeptinib, which are currently in clinical trials. A conference call is scheduled for the same day at 5:00 PM ET, accessible via toll-free numbers or webcast. Financial statements and management discussions will be available on SEDAR and EDGAR.

Aptose Biosciences has appointed Philippe Ledru as the new Chief Commercial Officer, effective immediately. Ledru brings over 30 years of pharmaceutical experience, with prior roles at Merck and Novartis, focusing on oncology product development. His expertise will support the commercialization of Aptose's lead drug, HM43239, aimed at treating acute myeloid leukemia. Concurrently, CFO Jotin Marango has resigned to pursue another opportunity, and CEO William G. Rice will temporarily handle the financial responsibilities until a new CFO is appointed.

Aptose Biosciences (NASDAQ: APTO) announced its participation in Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference. William G. Rice, Ph.D., Chairman and CEO, will discuss innovative treatments for acute myeloid leukemia (AML) on April 14, 2022, from 1:30 to 2:30 PM ET. The event, moderated by John Newman, will feature a panel titled 'Attacking AML: New Approaches.' The audio webcast can be accessed via Aptose's website. The company focuses on developing precision therapies for hematologic malignancies, with ongoing Phase 1 trials for its investigational products.